Imunon, Inc. (NASDAQ:IMNN – Get Free Report) was the recipient of a large increase in short interest during the month of September. As of September 15th, there was short interest totalling 473,600 shares, an increase of 23.7% from the August 31st total of 382,800 shares. Based on an average daily trading volume, of 2,950,000 shares, the days-to-cover ratio is currently 0.2 days. Currently, 3.5% of the shares of the company are sold short.
Imunon Price Performance
Shares of NASDAQ IMNN remained flat at $1.04 during mid-day trading on Monday. The stock had a trading volume of 37,106 shares, compared to its average volume of 1,110,582. Imunon has a twelve month low of $0.48 and a twelve month high of $3.65. The firm has a market cap of $9.78 million, a PE ratio of -0.51 and a beta of 2.13. The business’s 50-day moving average is $1.18 and its 200 day moving average is $1.26.
Imunon (NASDAQ:IMNN – Get Free Report) last announced its earnings results on Wednesday, August 14th. The company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.04. As a group, equities analysts expect that Imunon will post -1.71 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
View Our Latest Stock Analysis on IMNN
About Imunon
Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.
See Also
- Five stocks we like better than Imunon
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge
- What is a Low P/E Ratio and What Does it Tell Investors?
- Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Up 90% and Still Running: On Holding Stock’s Remarkable Climb
Receive News & Ratings for Imunon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imunon and related companies with MarketBeat.com's FREE daily email newsletter.